We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene (CNC) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Centene (CNC - Free Report) closed at $45.36 in the latest trading session, marking a +0.73% move from the prior day. This move outpaced the S&P 500's daily gain of 0.66%. Elsewhere, the Dow gained 1%, while the tech-heavy Nasdaq added 0.38%.
Heading into today, shares of the healthcare company had lost 16.3% over the past month, lagging the Medical sector's loss of 3.19% and the S&P 500's loss of 5.01% in that time.
Investors will be hoping for strength from CNC as it approaches its next earnings release. In that report, analysts expect CNC to post earnings of $0.97 per share. This would mark year-over-year growth of 7.78%. Meanwhile, our latest consensus estimate is calling for revenue of $18.36 billion, up 13.45% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.42 per share and revenue of $73.68 billion, which would represent changes of +24.86% and +22.56%, respectively, from the prior year.
Any recent changes to analyst estimates for CNC should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. CNC currently has a Zacks Rank of #3 (Hold).
In terms of valuation, CNC is currently trading at a Forward P/E ratio of 10.2. This represents a discount compared to its industry's average Forward P/E of 14.78.
Meanwhile, CNC's PEG ratio is currently 0.72. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CNC's industry had an average PEG ratio of 1.04 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 67, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CNC in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Centene (CNC) Outpaces Stock Market Gains: What You Should Know
Centene (CNC - Free Report) closed at $45.36 in the latest trading session, marking a +0.73% move from the prior day. This move outpaced the S&P 500's daily gain of 0.66%. Elsewhere, the Dow gained 1%, while the tech-heavy Nasdaq added 0.38%.
Heading into today, shares of the healthcare company had lost 16.3% over the past month, lagging the Medical sector's loss of 3.19% and the S&P 500's loss of 5.01% in that time.
Investors will be hoping for strength from CNC as it approaches its next earnings release. In that report, analysts expect CNC to post earnings of $0.97 per share. This would mark year-over-year growth of 7.78%. Meanwhile, our latest consensus estimate is calling for revenue of $18.36 billion, up 13.45% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.42 per share and revenue of $73.68 billion, which would represent changes of +24.86% and +22.56%, respectively, from the prior year.
Any recent changes to analyst estimates for CNC should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. CNC currently has a Zacks Rank of #3 (Hold).
In terms of valuation, CNC is currently trading at a Forward P/E ratio of 10.2. This represents a discount compared to its industry's average Forward P/E of 14.78.
Meanwhile, CNC's PEG ratio is currently 0.72. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CNC's industry had an average PEG ratio of 1.04 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 67, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CNC in the coming trading sessions, be sure to utilize Zacks.com.